Teva's Q2 revenues flat on European rise, U.S. fall

The good news from Teva Pharmaceutical Industries: Last year's acquisition of Ratiopharm hiked European sales for the second quarter. The not-so-good: A lack of new product introductions and erosion in sales of key products offset that rise, leaving sales flat. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.